ATI-052 Phase 1b POC Results Update - ACLARIS THERAPEUTICS INC

Explicit Guidance:

• Clinical Milestones:
  • EOE Phase IIb study expected to start "early next year" (early 2027).
  • Lichen Planus (LP) "monzatinib" trial (mucosal cohort) expected to initiate in the "coming couple weeks."
  • LP interim analysis expected later in 2027 upon enrollment of 60% of the mucosal cohort.
  • EOE top-line data and regulatory discussions anticipated in 2028 based on the 2b-3 seamless design.
  • IND filing for ITK inhibitor "ETI-9494" expected "this quarter" (Q4 2026), kicking off a series of catalysts in 2027.
  • Top-line data readout for T-slip mAb "Bosacatug" in Atopic Dermatitis expected "later this quarter" (Q4 2026).
• Financial:
  • Secured $50 million top-up financing.
  • Cash runway extended from end of 2028 to mid-year 2029.
  • Strategic focus on capital-efficient indications to fully fund EOE, LP, and next-gen ITK inhibitor programs.

Business-Segment Outlook:

• Atopic Dermatitis (AD):
  • Pipeline Strategy: Shifting capital from AD/asthma Phase IIb to Eosinophilic Esophagitis (EOE); AD remains under evaluation but deprioritized for immediate Phase IIb initiation.
  • Efficacy Expectations: Anticipates potential for higher efficacy (IGA-Clear/Clearance) and sustained durability (remittive effects) post-loading doses, though specific Phase IIb targets are not yet quantified.
  • Patient Focus: Future trials will likely include a mix of moderate-to-severe populations, contrasting the current severe (IGA-4) POC population.
• Eosinophilic Esophagitis (EOE):
  • Priority: Selected as the primary next indication for ATI-052 due to strong mechanistic fit (IL-4R + T-slip), growing global market, open competitive space, and lower capital intensity compared to asthma or AD.
  • Trial Design: Intent to execute a seamless Phase IIb-III study starting early 2027.
  • Endpoints: Planning a dose-ranging Phase IIb to identify optimal dose; histological remission selected as a sensitive Phase IIb endpoint; co-primary endpoints for Phase III to match the tezolimumab program.
  • Dosing Expectations: Targeting monthly maintenance dosing as a minimum, with aspirations for longer intervals; induction regimen to likely utilize standard "day 0 and week 2" dosing.
• Asthma:
  • Status: POC results show rapid response in both eosinophil-high and eosinophil-low patients; ongoing data collection.
  • Future: No immediate plan to launch Phase IIb; data will be collected to support future indication selection if EOE is not the sole bispecific path.
• Oral Small Molecules (LP):
  • Monzatinib: Fast-track designation already received; basket trial design focused on mucosal Lichen Planus with primary endpoint of ODSS (Oral Disease Severity Score).
  • Path to Registration: Intent to engage the FDA for potential conversion to a registrational study in the 60% cohort if interim data is supportive.
• ITK Inhibitor (ETI-9494):
  • Development: IND filing imminent; subsequent clinical trials planned for 2027.

Market and Competitive Outlook:

• Differentiation Strategy: ATI-052 aims to differentiate from dupilumab via broader mechanism (T-slip + IL-4R), addressing Th1, Th2, and Th17 endotypes to capture patients with heterogeneous or severe disease (including Th17-dominant populations like Black and Asian patients) who are often partial responders to dupilumab alone.
• Safety Advantage: Management anticipates avoiding conjunctivitis (a known risk with dupilumab) and potentially mitigating Th1/Th17 skewing (rashes, seronegative arthritis) due to broader immune suppression.
• Dosing Convenience: Targeting quarterly dosing as a "sweet spot" for AD, potentially monthly for EOE, aiming to outperform dupilumab's bi-weekly schedule.
• Oral vs. Injectable: Observes market shift where patients increasingly accept injectables (e.g., GLP-1s) over orals; dermatologist prescriber inertia is a hurdle but manageable given efficacy gains.
• Competitive Landscape: EOE viewed as less capital-intensive and with "ample open white space" compared to AD/Asthma; Tezolimumab's recent validation of T-slip in EOE reinforces the bispecific approach.

Macro / Industry Outlook:

• Regulatory Path: Utilizing FDA FastTrack designation for Monzatinib (LP) to enable expedited pathways and potential early registrational conversion.
• Seamless Trials: Anticipates success with seamless Phase IIb-III designs for EOE to reduce time-to-market and avoid separate study startups.
• Capital Allocation: Strategy emphasizes "disciplined capital allocation," favoring indications with higher probability of "finish line" success for a smaller biotech entity (EOE) over highly competitive, capital-heavy markets (AD/Asthma).

Strategic Initiatives:

• Capital Raise: Completed $50 million financing to fund EOE, potential second bispecific indication, LP, and next-gen ITK inhibitor.
• Indication Prioritization: Executive decision to pivot ATI-052 development toward EOE to maximize capital efficiency and de-risk the program.
• Parallel Advancement: Concurrently advancing oral small molecule (LP) and ITK inhibitor (ETI-9494) programs to diversify the portfolio catalysts in 2027.
• Dosing Optimization: Planning to test various dosing regimens (induction vs. maintenance frequency) in upcoming trials to maximize convenience without compromising efficacy.

Risks and Headwinds to Outlook:

• Trial Design Execution: The seamless Phase IIb-III EOE trial requires successful dose-ranging results to justify rolling into Phase III; regulatory acceptance of this design is a factor.
• Data Readout Timing: Reliance on future data points (Bosacatug AD data, LP interim data, EOE top-line data) to validate the T-slip hypothesis and guide final registration strategies.
• Capital Efficiency Constraints: As a small company, the firm must carefully manage cash burn; failure to progress EOE or LP as expected could strain the extended 2029 runway.
• Unspecified Indication: While EOE is the priority, the company still "evaluates the potential for one additional indication" for ATI-052, introducing uncertainty regarding the second line of business.
• Patient Recruitment/Response: High variability in patient severity (IGA-3 vs. IGA-4) and endotypes may impact response rates in broader Phase IIb/III populations compared to the POC severe cohort.

Management Tone on the Future:

• Confidence Level: High confidence in the "additivity or synergy" of the dual mechanism, citing "compelling proof of concept" and "complete normalization of the skin proteome."
• Sentiment: Extremely optimistic regarding the potential to "raise the bar" for efficacy in Type 2 diseases; describes the POC results as "better than expected" and "encouraging."
• Hedges: Standard legal disclaimers regarding forward-looking statements; acknowledges that Phase IIb data will be required to fully validate the strategy.
• Strategic Pivot: Demonstrates decisive leadership by pivoting resources to EOE despite strong AD data, prioritizing capital efficiency and "taking an indication all the way to the finish line."

Miscellaneous:

• Patient Population Details: POC AD trial enrolled 14 patients (82% IGA-4, severe); POC Asthma trial enrolled 16 patients with heterogeneous baseline FEV1 (50% with normal lung function).
• Biomarker Validation: Data confirms broad suppression of Th1, Th2, Th17, and Th22 pathways; reduction in IL-5 and eosinophils observed, differentiating from IL-4R blockade alone.
• Safety Profile: Zero cases of conjunctivitis across all clinical studies to date; no SAEs or discontinuations due to AEs in POC trials.
• Durability: Response durability noted up to 16 weeks in AD without maintenance dosing post-week 4; zero patients in the active group required rescue medication.